Detalhe da pesquisa
1.
Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61): a single-arm, multicentre, phase 2 trial.
Lancet Oncol
; 24(8): 881-891, 2023 08.
Artigo
Inglês
| MEDLINE | ID: mdl-37451291
2.
Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial.
Lancet
; 398(10295): 131-142, 2021 07 10.
Artigo
Inglês
| MEDLINE | ID: mdl-34246347
3.
Pembrolizumab with or Without Lenvatinib as First-line Therapy for Patients with Advanced Urothelial Carcinoma (LEAP-011): A Phase 3, Randomized, Double-Blind Trial.
Eur Urol
; 85(3): 229-238, 2024 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-37778952
4.
Advanced enteral therapy in acute pancreatitis: is there a room for immunonutrition? A meta-analysis.
Int J Surg
; 6(2): 119-24, 2008 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-18325863